Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer

Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer

Abstract Pancreatic cancer (PC) is among the most aggressive malignancies associated with a 5-year survival rate of <9%, and the treatment options remain limited. Antibody–drug conjugates (ADCs) are a new class of anticancer agents with superior efficacy and safety profiles. We studied the antitu...

Full description

Bibliographic Details
Main Authors: Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Format: Article
Language:English
Published: Nature Publishing Group 2023-04-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-023-05820-1

Internet

https://doi.org/10.1038/s41419-023-05820-1

Similar Items